Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978730 | 0.95 | CTSB (0.50) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL8242872 | 0.95 | CTSB (0.48) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL2215312 | 0.95 | CTSB (0.48) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL17212947 | 0.94 | CTSB (0.44) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL1688355 | 0.93 | CTSB (0.53) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL16021111 | 0.93 | CTSS (0.41) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL13385446 | 0.91 | CTSB (0.42) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL8250301 | 0.91 | CTSB (0.42) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL9978732 | 0.89 | CTSB (0.48) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL7873605 | 0.89 | CTSB (0.45) | CTSBPPP3CBCTSSCYP3A4ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R & D IRELAND (IE) | 2015-08-06 | — | — | US | disclosed |
| US-8754106-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-17 | — | — | US | disclosed |
| US-8741926-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-03 | — | — | US | disclosed |
| US-20130217725-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | MEDIVIR AB (SE) | 2013-08-22 | — | — | US | disclosed |
| US-20130089520-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | MEDIVIR AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-8349869-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2013-01-08 | — | — | US | disclosed |
| US-8148399-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-03 | — | — | US | disclosed |
| US-8148399-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-03 | — | — | US | disclosed |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-12-01 | — | — | US | disclosed |
| EP-2322516-A1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | Tibotec Pharmaceuticals Ltd. (IE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2007014926-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTSB 3370/4885PPP3CB 2809/4885CTSS 1949/4885 |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | CYP2A7, CYP3A7, HCCS | CTSB 3370/4885PPP3CB 2809/4885CTSS 1949/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTSB 3370/4885PPP3CB 2809/4885CTSS 1949/4885 |
| US-20130217725-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTSB 3370/4885PPP3CB 2809/4885CTSS 1949/4885 |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, HCCS, CYP3A7 | CTSB 3274/4885PPP3CB 2900/4885CTSS 1858/4885 |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTSB 3370/4885PPP3CB 2809/4885CTSS 1949/4885 |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | CTSB 260/4885PPP3CB 987/4885CTSS 565/4885 |
| US-20130089520-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTSB 3370/4885PPP3CB 2809/4885CTSS 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.